Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers

At registration (pre-transplant) * Haematological cancer which can be ONE OF the following: * Non-Hodgkin's lymphoma (NHL) in CR or PR * Hodgkin's lymphoma (HL) in CR or PR * Chronic (Pro-)lymphocytic leukaemia (CLL/PLL) in CR or PR * Plasma cell myeloma (PCM) in CR, VGPR or PR * Acute myeloid leukaemia (AML) in CR * Acute lymphoblastic leukaemia (ALL) in CR * Myelodysplastic syndrome (MDS) \< 10% blasts in bone marrow * Chronic myelomonocytic leukaemia (CMML) \< 10% blasts in bone marrow * Have undergone disease reassessment within 8 weeks prior to registration * HLA-identical sibling transplant to be performed using one of the following reduced intensity alemtuzumab-containing conditioning regimens: * Fludarabine-busulphan-alemtuzumab * Fludarabine-melphalan-alemtuzumab * BCNU-etoposide-cytarabine-melphalan (BEAM)-alemtuzumab * CCNU-etoposide-cytarabine-melphalan (LEAM)-alemtuzumab * Aged ≥18 years, and \<70 years * Written informed consent Exclusion Criteria * Women who are pregnant or breast-feeding * Life expectancy of \<8 weeks * Currently taking part in any other interventional clinical research study (involving any IMP, ATMP or cellular therapy) * Organ dysfunction: Creatinine \>200μmol/l, Bilirubin \>50μmol/l, or AST/ALT \> 3x ULN Post-transplant * Active acute GvHD * Prior grade II-IV GvHD * Relapse or progressive disease * Primary or secondary graft failure * Other cellular therapies * Requirement for ongoing immunosuppression